Ihab Kamel
Concepts (627)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Neoplasms | 118 | 2024 | 784 | 22.230 |
Why?
| | Carcinoma, Hepatocellular | 71 | 2024 | 360 | 16.800 |
Why?
| | Chemoembolization, Therapeutic | 42 | 2024 | 91 | 12.830 |
Why?
| | Diffusion Magnetic Resonance Imaging | 46 | 2024 | 153 | 11.450 |
Why?
| | Magnetic Resonance Imaging | 137 | 2025 | 3566 | 11.180 |
Why?
| | Pancreatic Neoplasms | 33 | 2024 | 931 | 6.320 |
Why?
| | Cholangiocarcinoma | 16 | 2024 | 104 | 5.220 |
Why?
| | Contrast Media | 57 | 2025 | 462 | 4.840 |
Why?
| | Image Enhancement | 27 | 2018 | 190 | 4.720 |
Why?
| | Tomography, X-Ray Computed | 66 | 2024 | 2677 | 4.550 |
Why?
| | Carcinoma, Pancreatic Ductal | 14 | 2024 | 285 | 4.410 |
Why?
| | Image Interpretation, Computer-Assisted | 22 | 2025 | 267 | 4.080 |
Why?
| | Bile Duct Neoplasms | 13 | 2023 | 123 | 4.030 |
Why?
| | Liver | 38 | 2025 | 1938 | 3.860 |
Why?
| | Neuroendocrine Tumors | 12 | 2021 | 115 | 3.400 |
Why?
| | Liver Cirrhosis | 20 | 2024 | 316 | 3.160 |
Why?
| | Elasticity Imaging Techniques | 9 | 2023 | 60 | 2.970 |
Why?
| | Liver Diseases | 16 | 2023 | 311 | 2.750 |
Why?
| | Pancreatic Cyst | 12 | 2023 | 60 | 2.720 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 16 | 2022 | 57 | 2.610 |
Why?
| | Retrospective Studies | 101 | 2025 | 15564 | 2.580 |
Why?
| | Tumor Burden | 13 | 2024 | 309 | 2.520 |
Why?
| | Middle Aged | 168 | 2025 | 33200 | 2.500 |
Why?
| | Gadolinium DTPA | 20 | 2025 | 70 | 2.460 |
Why?
| | Cholangitis, Sclerosing | 4 | 2020 | 75 | 2.390 |
Why?
| | Aged | 136 | 2025 | 23729 | 2.260 |
Why?
| | Algorithms | 19 | 2025 | 1686 | 2.250 |
Why?
| | Humans | 315 | 2025 | 136783 | 2.250 |
Why?
| | Cystadenoma, Serous | 3 | 2024 | 21 | 2.070 |
Why?
| | Pancreatitis | 8 | 2023 | 132 | 2.060 |
Why?
| | Sensitivity and Specificity | 35 | 2023 | 1942 | 1.980 |
Why?
| | Male | 182 | 2025 | 67361 | 1.920 |
Why?
| | Female | 193 | 2025 | 72840 | 1.900 |
Why?
| | Positron-Emission Tomography | 10 | 2023 | 295 | 1.850 |
Why?
| | Reproducibility of Results | 40 | 2025 | 3272 | 1.850 |
Why?
| | Pancreas | 13 | 2024 | 328 | 1.810 |
Why?
| | Colorectal Neoplasms | 10 | 2021 | 792 | 1.690 |
Why?
| | Esophageal Neoplasms | 12 | 2024 | 324 | 1.630 |
Why?
| | Spleen | 4 | 2020 | 513 | 1.620 |
Why?
| | Carcinoma, Renal Cell | 6 | 2024 | 214 | 1.570 |
Why?
| | Treatment Outcome | 56 | 2024 | 10764 | 1.560 |
Why?
| | Adult | 112 | 2025 | 37616 | 1.560 |
Why?
| | Incidental Findings | 5 | 2024 | 87 | 1.550 |
Why?
| | Kidney Neoplasms | 7 | 2025 | 400 | 1.540 |
Why?
| | Splenic Diseases | 3 | 2019 | 8 | 1.530 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 6 | 2020 | 24 | 1.490 |
Why?
| | Iron Overload | 4 | 2024 | 17 | 1.460 |
Why?
| | Aged, 80 and over | 53 | 2024 | 7569 | 1.460 |
Why?
| | Diagnosis, Differential | 24 | 2025 | 1483 | 1.440 |
Why?
| | Embolization, Therapeutic | 11 | 2022 | 229 | 1.430 |
Why?
| | Adenoma, Liver Cell | 4 | 2024 | 5 | 1.430 |
Why?
| | Lymphatic Metastasis | 5 | 2024 | 350 | 1.280 |
Why?
| | Image Processing, Computer-Assisted | 16 | 2025 | 752 | 1.270 |
Why?
| | Angiomyolipoma | 3 | 2018 | 24 | 1.260 |
Why?
| | Diagnostic Imaging | 14 | 2024 | 331 | 1.240 |
Why?
| | Hepatectomy | 17 | 2021 | 249 | 1.230 |
Why?
| | Ureteral Obstruction | 2 | 2020 | 64 | 1.220 |
Why?
| | Focal Nodular Hyperplasia | 5 | 2018 | 8 | 1.190 |
Why?
| | Adipose Tissue | 7 | 2024 | 629 | 1.170 |
Why?
| | Rectal Neoplasms | 6 | 2024 | 149 | 1.170 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1683 | 1.160 |
Why?
| | Imaging, Three-Dimensional | 14 | 2018 | 576 | 1.160 |
Why?
| | Organometallic Compounds | 4 | 2018 | 111 | 1.150 |
Why?
| | Uterine Neoplasms | 4 | 2023 | 109 | 1.150 |
Why?
| | Prognosis | 26 | 2024 | 4018 | 1.150 |
Why?
| | Adenoma | 4 | 2024 | 230 | 1.130 |
Why?
| | Neoplasm Staging | 20 | 2024 | 1373 | 1.120 |
Why?
| | Kidney Diseases | 3 | 2020 | 406 | 1.100 |
Why?
| | ROC Curve | 17 | 2024 | 545 | 1.090 |
Why?
| | Ultrasonography | 5 | 2024 | 751 | 1.040 |
Why?
| | Liver Transplantation | 14 | 2025 | 871 | 1.030 |
Why?
| | Yttrium Radioisotopes | 5 | 2022 | 57 | 1.030 |
Why?
| | Predictive Value of Tests | 23 | 2024 | 2030 | 1.020 |
Why?
| | Survival Rate | 18 | 2024 | 1969 | 1.010 |
Why?
| | Carcinoma | 6 | 2023 | 236 | 0.970 |
Why?
| | Neoadjuvant Therapy | 9 | 2024 | 403 | 0.960 |
Why?
| | Magnetic Resonance Angiography | 3 | 2018 | 240 | 0.960 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 368 | 0.950 |
Why?
| | Urinary Bladder Neoplasms | 7 | 2022 | 250 | 0.950 |
Why?
| | Coronavirus Infections | 2 | 2020 | 359 | 0.940 |
Why?
| | Leiomyoma | 3 | 2023 | 77 | 0.930 |
Why?
| | Bile Ducts, Intrahepatic | 10 | 2023 | 78 | 0.930 |
Why?
| | Cardiomyopathy, Hypertrophic | 8 | 2018 | 142 | 0.920 |
Why?
| | Nomograms | 2 | 2024 | 54 | 0.920 |
Why?
| | Fibrosis | 8 | 2021 | 551 | 0.910 |
Why?
| | Neoplasm Grading | 6 | 2024 | 306 | 0.910 |
Why?
| | Societies, Medical | 16 | 2024 | 820 | 0.890 |
Why?
| | Adenomyosis | 1 | 2023 | 4 | 0.860 |
Why?
| | Infusions, Intra-Arterial | 6 | 2019 | 59 | 0.860 |
Why?
| | Doxorubicin | 9 | 2014 | 365 | 0.860 |
Why?
| | Uterine Artery Embolization | 1 | 2023 | 7 | 0.860 |
Why?
| | Gallbladder Neoplasms | 1 | 2023 | 23 | 0.850 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2019 | 77 | 0.840 |
Why?
| | Liver Regeneration | 6 | 2017 | 46 | 0.840 |
Why?
| | Leiomyosarcoma | 2 | 2022 | 28 | 0.830 |
Why?
| | Magnetic Resonance Spectroscopy | 7 | 2022 | 616 | 0.830 |
Why?
| | Neoplasms | 7 | 2021 | 2644 | 0.820 |
Why?
| | Antineoplastic Agents | 9 | 2019 | 2129 | 0.810 |
Why?
| | Living Donors | 4 | 2021 | 295 | 0.800 |
Why?
| | Adenocarcinoma | 7 | 2020 | 936 | 0.800 |
Why?
| | Prospective Studies | 29 | 2025 | 7583 | 0.780 |
Why?
| | Immunotherapy | 2 | 2024 | 640 | 0.740 |
Why?
| | Hemangioma | 4 | 2022 | 48 | 0.740 |
Why?
| | Patient Safety | 1 | 2024 | 304 | 0.720 |
Why?
| | Fluorodeoxyglucose F18 | 3 | 2022 | 135 | 0.720 |
Why?
| | Renal Artery | 2 | 2020 | 37 | 0.710 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2023 | 351 | 0.700 |
Why?
| | Meglumine | 3 | 2018 | 18 | 0.700 |
Why?
| | Risk Assessment | 11 | 2024 | 3429 | 0.690 |
Why?
| | Multidetector Computed Tomography | 6 | 2024 | 39 | 0.680 |
Why?
| | Evidence-Based Medicine | 12 | 2024 | 738 | 0.670 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 2 | 2019 | 211 | 0.670 |
Why?
| | Obesity, Abdominal | 1 | 2020 | 48 | 0.670 |
Why?
| | Adenocarcinoma, Mucinous | 3 | 2018 | 80 | 0.670 |
Why?
| | Diffusion Tensor Imaging | 2 | 2021 | 79 | 0.660 |
Why?
| | Catheter Ablation | 8 | 2018 | 349 | 0.660 |
Why?
| | Subcutaneous Fat | 1 | 2020 | 81 | 0.660 |
Why?
| | Vascular Diseases | 2 | 2017 | 244 | 0.660 |
Why?
| | Necrosis | 5 | 2021 | 244 | 0.650 |
Why?
| | Biomarkers, Tumor | 8 | 2016 | 1274 | 0.630 |
Why?
| | Follow-Up Studies | 20 | 2022 | 5115 | 0.620 |
Why?
| | Kidney | 7 | 2025 | 1463 | 0.620 |
Why?
| | Observer Variation | 8 | 2020 | 345 | 0.610 |
Why?
| | Young Adult | 31 | 2024 | 13126 | 0.610 |
Why?
| | Radiology | 6 | 2019 | 181 | 0.610 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2019 | 38 | 0.600 |
Why?
| | Adenoma, Oxyphilic | 1 | 2018 | 7 | 0.590 |
Why?
| | Biliary Tract Diseases | 4 | 2019 | 39 | 0.580 |
Why?
| | Hepatic Artery | 3 | 2013 | 61 | 0.570 |
Why?
| | Niacinamide | 3 | 2015 | 78 | 0.570 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2018 | 57 | 0.570 |
Why?
| | Phenylurea Compounds | 3 | 2015 | 95 | 0.570 |
Why?
| | Angiography | 4 | 2013 | 207 | 0.560 |
Why?
| | Biomarkers | 9 | 2021 | 4158 | 0.550 |
Why?
| | Betacoronavirus | 1 | 2020 | 267 | 0.550 |
Why?
| | Pancreatic Ducts | 2 | 2015 | 85 | 0.550 |
Why?
| | Whole Body Imaging | 3 | 2018 | 25 | 0.550 |
Why?
| | Defibrillators, Implantable | 6 | 2022 | 315 | 0.550 |
Why?
| | Tachycardia, Ventricular | 5 | 2022 | 174 | 0.540 |
Why?
| | Magnetic Resonance Imaging, Cine | 5 | 2022 | 193 | 0.540 |
Why?
| | Early Detection of Cancer | 9 | 2024 | 419 | 0.540 |
Why?
| | Actins | 1 | 2019 | 415 | 0.540 |
Why?
| | Positron Emission Tomography Computed Tomography | 4 | 2022 | 98 | 0.530 |
Why?
| | Lymph Nodes | 5 | 2024 | 492 | 0.530 |
Why?
| | Cystadenoma, Mucinous | 1 | 2016 | 13 | 0.520 |
Why?
| | Watchful Waiting | 1 | 2016 | 80 | 0.500 |
Why?
| | Kaplan-Meier Estimate | 11 | 2018 | 891 | 0.490 |
Why?
| | Heart Ventricles | 8 | 2018 | 792 | 0.490 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2016 | 89 | 0.480 |
Why?
| | Liver Function Tests | 3 | 2025 | 114 | 0.460 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 3 | 2025 | 107 | 0.460 |
Why?
| | Sarcopenia | 6 | 2016 | 82 | 0.460 |
Why?
| | Leucovorin | 2 | 2024 | 82 | 0.450 |
Why?
| | Choledochal Cyst | 3 | 2022 | 19 | 0.450 |
Why?
| | Multimodal Imaging | 3 | 2023 | 116 | 0.450 |
Why?
| | Bile Ducts | 3 | 2019 | 71 | 0.440 |
Why?
| | Lupus Nephritis | 2 | 2025 | 63 | 0.430 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2023 | 1055 | 0.430 |
Why?
| | Esophageal and Gastric Varices | 2 | 2024 | 40 | 0.430 |
Why?
| | Neoplasm Invasiveness | 4 | 2020 | 507 | 0.430 |
Why?
| | Fluorouracil | 2 | 2024 | 210 | 0.420 |
Why?
| | Biliary Tract Neoplasms | 1 | 2013 | 30 | 0.420 |
Why?
| | Survival Analysis | 6 | 2019 | 1319 | 0.420 |
Why?
| | Aspartate Aminotransferases | 1 | 2013 | 90 | 0.420 |
Why?
| | Choline | 2 | 2011 | 131 | 0.410 |
Why?
| | Alanine Transaminase | 1 | 2013 | 157 | 0.410 |
Why?
| | Proportional Hazards Models | 10 | 2018 | 1260 | 0.400 |
Why?
| | Iron | 3 | 2024 | 311 | 0.400 |
Why?
| | Organ Size | 6 | 2019 | 477 | 0.400 |
Why?
| | Fatty Liver | 4 | 2017 | 242 | 0.400 |
Why?
| | Death, Sudden, Cardiac | 5 | 2022 | 184 | 0.400 |
Why?
| | Phantoms, Imaging | 5 | 2021 | 151 | 0.390 |
Why?
| | Ventricular Fibrillation | 3 | 2018 | 60 | 0.390 |
Why?
| | United States | 28 | 2024 | 14660 | 0.390 |
Why?
| | Ventricular Function, Right | 3 | 2020 | 283 | 0.390 |
Why?
| | Abdominal Pain | 4 | 2023 | 145 | 0.390 |
Why?
| | Practice Guidelines as Topic | 6 | 2024 | 1568 | 0.380 |
Why?
| | Abdomen | 1 | 2013 | 125 | 0.380 |
Why?
| | Models, Biological | 2 | 2016 | 1769 | 0.370 |
Why?
| | Authorship | 1 | 2012 | 52 | 0.370 |
Why?
| | Risk Factors | 23 | 2024 | 10331 | 0.370 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2025 | 257 | 0.370 |
Why?
| | Area Under Curve | 3 | 2019 | 313 | 0.370 |
Why?
| | Myocardial Perfusion Imaging | 3 | 2025 | 40 | 0.370 |
Why?
| | Carcinoma in Situ | 3 | 2021 | 49 | 0.360 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2011 | 31 | 0.360 |
Why?
| | Ethiodized Oil | 3 | 2021 | 8 | 0.360 |
Why?
| | Endosonography | 5 | 2020 | 156 | 0.350 |
Why?
| | Arrhythmias, Cardiac | 5 | 2022 | 331 | 0.350 |
Why?
| | Cohort Studies | 11 | 2024 | 5718 | 0.350 |
Why?
| | Cystadenoma | 3 | 2023 | 6 | 0.350 |
Why?
| | Embolism | 1 | 2011 | 41 | 0.350 |
Why?
| | Radiopharmaceuticals | 4 | 2019 | 178 | 0.350 |
Why?
| | Echo-Planar Imaging | 3 | 2023 | 21 | 0.340 |
Why?
| | Tomography, Spiral Computed | 4 | 2007 | 32 | 0.340 |
Why?
| | Publishing | 1 | 2012 | 146 | 0.340 |
Why?
| | Breast Neoplasms | 6 | 2021 | 2239 | 0.340 |
Why?
| | Angiomatosis | 1 | 2010 | 5 | 0.340 |
Why?
| | Radiologists | 3 | 2024 | 50 | 0.330 |
Why?
| | Bevacizumab | 3 | 2021 | 136 | 0.330 |
Why?
| | SEER Program | 3 | 2024 | 218 | 0.330 |
Why?
| | Artificial Intelligence | 3 | 2022 | 272 | 0.320 |
Why?
| | Myocardium | 5 | 2018 | 1002 | 0.320 |
Why?
| | Disease Progression | 7 | 2019 | 2750 | 0.320 |
Why?
| | Cystadenocarcinoma | 2 | 2023 | 4 | 0.320 |
Why?
| | Periodicals as Topic | 1 | 2012 | 210 | 0.320 |
Why?
| | Software | 4 | 2018 | 663 | 0.320 |
Why?
| | Autoimmune Diseases | 1 | 2013 | 459 | 0.310 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2021 | 278 | 0.310 |
Why?
| | Ventricular Dysfunction, Right | 2 | 2025 | 236 | 0.310 |
Why?
| | Solitary Fibrous Tumors | 1 | 2008 | 5 | 0.300 |
Why?
| | Secretin | 3 | 2019 | 6 | 0.300 |
Why?
| | Eye Neoplasms | 1 | 2008 | 18 | 0.300 |
Why?
| | Radiographic Image Enhancement | 2 | 2012 | 58 | 0.290 |
Why?
| | Chi-Square Distribution | 6 | 2017 | 532 | 0.280 |
Why?
| | Heart Atria | 2 | 2018 | 136 | 0.280 |
Why?
| | Drug Delivery Systems | 1 | 2011 | 362 | 0.280 |
Why?
| | Sentinel Surveillance | 2 | 2018 | 47 | 0.270 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 2 | 2024 | 18 | 0.270 |
Why?
| | Rectum | 3 | 2020 | 185 | 0.270 |
Why?
| | Leiomyomatosis | 1 | 2007 | 6 | 0.270 |
Why?
| | Pancreatectomy | 5 | 2020 | 252 | 0.270 |
Why?
| | Neovascularization, Pathologic | 2 | 2008 | 301 | 0.260 |
Why?
| | Psoas Muscles | 3 | 2015 | 13 | 0.260 |
Why?
| | Adolescent | 16 | 2022 | 21463 | 0.260 |
Why?
| | Myocardial Contraction | 2 | 2018 | 340 | 0.260 |
Why?
| | Ventricular Outflow Obstruction | 2 | 2016 | 43 | 0.240 |
Why?
| | Models, Statistical | 3 | 2019 | 658 | 0.240 |
Why?
| | Liver Failure | 2 | 2016 | 94 | 0.230 |
Why?
| | Amyloidosis | 1 | 2025 | 43 | 0.230 |
Why?
| | Disease Models, Animal | 4 | 2020 | 4279 | 0.230 |
Why?
| | Proteinuria | 1 | 2025 | 97 | 0.230 |
Why?
| | Collateral Circulation | 1 | 2004 | 19 | 0.220 |
Why?
| | Cardiomyopathies | 2 | 2025 | 350 | 0.220 |
Why?
| | Computed Tomography Angiography | 1 | 2025 | 124 | 0.220 |
Why?
| | Biopsy | 4 | 2025 | 1126 | 0.220 |
Why?
| | Scleroderma, Systemic | 1 | 2025 | 122 | 0.220 |
Why?
| | Pancreas, Exocrine | 1 | 2024 | 7 | 0.220 |
Why?
| | Rats, Sprague-Dawley | 2 | 2020 | 2481 | 0.220 |
Why?
| | Protons | 4 | 2020 | 90 | 0.220 |
Why?
| | Safety Management | 1 | 2024 | 119 | 0.210 |
Why?
| | Atrial Fibrillation | 2 | 2018 | 390 | 0.210 |
Why?
| | Hypertension, Portal | 1 | 2004 | 64 | 0.210 |
Why?
| | Feasibility Studies | 7 | 2024 | 947 | 0.210 |
Why?
| | Carcinoma, Papillary | 2 | 2014 | 81 | 0.210 |
Why?
| | Hepatic Veins | 1 | 2003 | 33 | 0.210 |
Why?
| | Cholecystitis, Acute | 1 | 2023 | 23 | 0.200 |
Why?
| | Pulmonary Embolism | 1 | 2025 | 220 | 0.200 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2024 | 132 | 0.200 |
Why?
| | Colitis, Ulcerative | 1 | 2024 | 135 | 0.200 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2023 | 56 | 0.200 |
Why?
| | Electrocardiography | 4 | 2020 | 628 | 0.200 |
Why?
| | Pancreatitis, Chronic | 2 | 2020 | 58 | 0.200 |
Why?
| | alpha-Fetoproteins | 2 | 2013 | 46 | 0.200 |
Why?
| | Hemangioma, Cavernous | 1 | 2022 | 15 | 0.200 |
Why?
| | Kasabach-Merritt Syndrome | 1 | 2022 | 8 | 0.200 |
Why?
| | Cysts | 1 | 2023 | 111 | 0.190 |
Why?
| | Statistics, Nonparametric | 5 | 2019 | 430 | 0.190 |
Why?
| | Ultrasonography, Mammary | 1 | 2021 | 13 | 0.180 |
Why?
| | Pandemics | 2 | 2020 | 1619 | 0.180 |
Why?
| | Single-Blind Method | 2 | 2017 | 286 | 0.180 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2022 | 128 | 0.180 |
Why?
| | Biomedical Research | 2 | 2022 | 689 | 0.180 |
Why?
| | Nuclear Medicine | 1 | 2021 | 9 | 0.180 |
Why?
| | Melanoma | 1 | 2008 | 757 | 0.180 |
Why?
| | Time Factors | 10 | 2018 | 6792 | 0.180 |
Why?
| | Semaphorins | 1 | 2021 | 32 | 0.180 |
Why?
| | Portal Vein | 4 | 2012 | 119 | 0.180 |
Why?
| | Rats | 2 | 2020 | 5628 | 0.180 |
Why?
| | Awards and Prizes | 1 | 2022 | 67 | 0.170 |
Why?
| | Crohn Disease | 1 | 2024 | 242 | 0.170 |
Why?
| | Cholestasis | 1 | 2023 | 232 | 0.170 |
Why?
| | Reference Values | 2 | 2020 | 817 | 0.170 |
Why?
| | Maryland | 3 | 2016 | 55 | 0.170 |
Why?
| | Cancer Care Facilities | 1 | 2021 | 38 | 0.170 |
Why?
| | Margins of Excision | 1 | 2020 | 50 | 0.170 |
Why?
| | Italy | 1 | 2020 | 106 | 0.170 |
Why?
| | Kidney Cortex | 1 | 2020 | 26 | 0.170 |
Why?
| | Inflammation | 1 | 2011 | 2834 | 0.170 |
Why?
| | Regression Analysis | 3 | 2018 | 1024 | 0.170 |
Why?
| | Rabbits | 3 | 2011 | 789 | 0.170 |
Why?
| | Kidney Medulla | 1 | 2020 | 35 | 0.170 |
Why?
| | Thorax | 1 | 2020 | 47 | 0.170 |
Why?
| | Ferric Compounds | 2 | 2012 | 55 | 0.170 |
Why?
| | Mammography | 1 | 2021 | 151 | 0.170 |
Why?
| | Esophageal Mucosa | 1 | 2020 | 22 | 0.160 |
Why?
| | Severity of Illness Index | 4 | 2016 | 2831 | 0.160 |
Why?
| | Ursodeoxycholic Acid | 1 | 2019 | 21 | 0.160 |
Why?
| | Digestive System Neoplasms | 1 | 2019 | 9 | 0.160 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2019 | 39 | 0.160 |
Why?
| | Cardiac-Gated Imaging Techniques | 2 | 2016 | 21 | 0.160 |
Why?
| | Recurrence | 2 | 2020 | 1058 | 0.160 |
Why?
| | Postoperative Complications | 4 | 2016 | 2624 | 0.160 |
Why?
| | Jaundice | 1 | 2019 | 14 | 0.160 |
Why?
| | Drug Therapy, Combination | 3 | 2024 | 1059 | 0.160 |
Why?
| | Mutation | 4 | 2015 | 3953 | 0.160 |
Why?
| | Pyridines | 3 | 2021 | 505 | 0.160 |
Why?
| | Ovarian Neoplasms | 1 | 2025 | 563 | 0.160 |
Why?
| | Microspheres | 5 | 2016 | 137 | 0.150 |
Why?
| | Jejunum | 1 | 2019 | 31 | 0.150 |
Why?
| | Benchmarking | 1 | 2020 | 183 | 0.150 |
Why?
| | Elasticity | 1 | 2019 | 197 | 0.150 |
Why?
| | Appendicitis | 1 | 2000 | 130 | 0.150 |
Why?
| | Epidemiologic Methods | 1 | 2019 | 96 | 0.150 |
Why?
| | Chronic Disease | 4 | 2017 | 1784 | 0.150 |
Why?
| | Gadolinium | 3 | 2021 | 82 | 0.150 |
Why?
| | Mucins | 1 | 2019 | 73 | 0.150 |
Why?
| | Cardiac Imaging Techniques | 2 | 2018 | 22 | 0.150 |
Why?
| | Vaccines | 1 | 2024 | 406 | 0.150 |
Why?
| | Artifacts | 2 | 2016 | 129 | 0.150 |
Why?
| | Atrophy | 2 | 2020 | 184 | 0.150 |
Why?
| | Gastrointestinal Agents | 1 | 2019 | 65 | 0.150 |
Why?
| | Brachytherapy | 1 | 2019 | 119 | 0.150 |
Why?
| | Pericardium | 1 | 2018 | 56 | 0.150 |
Why?
| | Viscera | 1 | 2018 | 17 | 0.150 |
Why?
| | Prevalence | 4 | 2023 | 2712 | 0.140 |
Why?
| | Animals | 10 | 2020 | 36768 | 0.140 |
Why?
| | Equipment Safety | 1 | 2017 | 37 | 0.140 |
Why?
| | Caloric Restriction | 1 | 2019 | 123 | 0.140 |
Why?
| | Hemochromatosis | 1 | 2017 | 10 | 0.140 |
Why?
| | Sepsis | 1 | 2024 | 611 | 0.140 |
Why?
| | Combined Modality Therapy | 5 | 2016 | 1235 | 0.140 |
Why?
| | Ventricular Flutter | 1 | 2017 | 2 | 0.140 |
Why?
| | Disease Susceptibility | 1 | 2019 | 344 | 0.140 |
Why?
| | Tomography, Emission-Computed | 2 | 2010 | 66 | 0.140 |
Why?
| | Metastasectomy | 1 | 2017 | 20 | 0.140 |
Why?
| | Pulmonary Veins | 1 | 2018 | 99 | 0.130 |
Why?
| | Adrenocortical Adenoma | 1 | 2016 | 2 | 0.130 |
Why?
| | Lymphography | 1 | 2016 | 10 | 0.130 |
Why?
| | Lung | 2 | 2020 | 4065 | 0.130 |
Why?
| | Breath Holding | 1 | 2016 | 9 | 0.130 |
Why?
| | Obesity | 3 | 2023 | 2975 | 0.130 |
Why?
| | Incidence | 6 | 2020 | 2788 | 0.130 |
Why?
| | Electric Countershock | 1 | 2017 | 107 | 0.130 |
Why?
| | Pacemaker, Artificial | 1 | 2017 | 119 | 0.130 |
Why?
| | Evaluation Studies as Topic | 1 | 2016 | 177 | 0.130 |
Why?
| | Motion | 1 | 2016 | 98 | 0.130 |
Why?
| | Benzamides | 1 | 2017 | 217 | 0.130 |
Why?
| | Body Water | 1 | 2016 | 21 | 0.130 |
Why?
| | Coronary Circulation | 2 | 2015 | 141 | 0.130 |
Why?
| | Primary Prevention | 1 | 2018 | 196 | 0.130 |
Why?
| | Neoplasms, Second Primary | 1 | 2017 | 115 | 0.130 |
Why?
| | Carcinoid Tumor | 2 | 2008 | 26 | 0.120 |
Why?
| | Platelet Count | 1 | 2016 | 86 | 0.120 |
Why?
| | Azacitidine | 1 | 2017 | 141 | 0.120 |
Why?
| | Bariatric Surgery | 1 | 2019 | 214 | 0.120 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2016 | 63 | 0.120 |
Why?
| | Echocardiography | 2 | 2016 | 659 | 0.120 |
Why?
| | Phosphorus | 1 | 2016 | 97 | 0.120 |
Why?
| | Pancreatitis, Acute Necrotizing | 1 | 2015 | 13 | 0.120 |
Why?
| | Fractures, Spontaneous | 2 | 2005 | 15 | 0.120 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2015 | 25 | 0.120 |
Why?
| | Patient Care Team | 1 | 2021 | 627 | 0.120 |
Why?
| | Adiposity | 1 | 2020 | 518 | 0.120 |
Why?
| | Telomere Homeostasis | 1 | 2015 | 33 | 0.120 |
Why?
| | Hospital Costs | 1 | 2016 | 119 | 0.120 |
Why?
| | Bone Neoplasms | 1 | 2018 | 248 | 0.120 |
Why?
| | Body Composition | 1 | 2019 | 677 | 0.120 |
Why?
| | Preoperative Care | 3 | 2024 | 356 | 0.120 |
Why?
| | Digestive System Surgical Procedures | 1 | 2016 | 106 | 0.120 |
Why?
| | Telomere | 2 | 2015 | 280 | 0.120 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2016 | 130 | 0.120 |
Why?
| | Fractures, Stress | 2 | 2005 | 35 | 0.120 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 682 | 0.120 |
Why?
| | Image-Guided Biopsy | 1 | 2014 | 39 | 0.110 |
Why?
| | Disease-Free Survival | 4 | 2022 | 687 | 0.110 |
Why?
| | Frail Elderly | 1 | 2015 | 129 | 0.110 |
Why?
| | Consensus | 1 | 2018 | 679 | 0.110 |
Why?
| | Acrylic Resins | 2 | 2012 | 46 | 0.110 |
Why?
| | Biliary Tract | 2 | 2012 | 17 | 0.110 |
Why?
| | Gelatin | 2 | 2012 | 50 | 0.110 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2012 | 130 | 0.110 |
Why?
| | Critical Illness | 1 | 2020 | 807 | 0.110 |
Why?
| | Gene Expression | 1 | 2019 | 1499 | 0.110 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2014 | 108 | 0.110 |
Why?
| | Abdomen, Acute | 1 | 2014 | 21 | 0.110 |
Why?
| | Cholecystitis | 1 | 2014 | 24 | 0.110 |
Why?
| | Fissure in Ano | 1 | 2013 | 4 | 0.110 |
Why?
| | Weight Loss | 1 | 2019 | 775 | 0.110 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2013 | 25 | 0.110 |
Why?
| | Ventricular Remodeling | 1 | 2016 | 262 | 0.110 |
Why?
| | Delayed-Action Preparations | 1 | 2014 | 180 | 0.110 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1513 | 0.110 |
Why?
| | Linear Models | 3 | 2011 | 845 | 0.110 |
Why?
| | Hypertension, Pulmonary | 1 | 2025 | 1902 | 0.110 |
Why?
| | Tetrazoles | 1 | 2013 | 40 | 0.100 |
Why?
| | Rectal Fistula | 1 | 2013 | 27 | 0.100 |
Why?
| | Dyspnea | 1 | 2015 | 251 | 0.100 |
Why?
| | Pattern Recognition, Automated | 1 | 2013 | 73 | 0.100 |
Why?
| | Cystic Fibrosis | 1 | 2023 | 1104 | 0.100 |
Why?
| | Carcinoma, Transitional Cell | 2 | 2005 | 71 | 0.100 |
Why?
| | Analysis of Variance | 2 | 2013 | 1318 | 0.100 |
Why?
| | Pelvic Neoplasms | 1 | 2013 | 26 | 0.100 |
Why?
| | Academic Medical Centers | 2 | 2013 | 497 | 0.100 |
Why?
| | Postoperative Period | 3 | 2016 | 343 | 0.100 |
Why?
| | Abdominal Neoplasms | 1 | 2013 | 39 | 0.100 |
Why?
| | Liver Circulation | 1 | 2012 | 20 | 0.100 |
Why?
| | Endoscopy, Digestive System | 2 | 2024 | 136 | 0.100 |
Why?
| | Logistic Models | 3 | 2013 | 2060 | 0.100 |
Why?
| | Iohexol | 1 | 2012 | 23 | 0.100 |
Why?
| | Radiography | 5 | 2022 | 829 | 0.100 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 1 | 2012 | 11 | 0.100 |
Why?
| | Acute Disease | 3 | 2023 | 1006 | 0.100 |
Why?
| | Polyvinyls | 1 | 2012 | 20 | 0.100 |
Why?
| | Vascular Neoplasms | 1 | 2012 | 18 | 0.100 |
Why?
| | Prednisone | 1 | 2013 | 243 | 0.100 |
Why?
| | Ventricular Function, Left | 1 | 2016 | 540 | 0.100 |
Why?
| | Imidazoles | 1 | 2013 | 239 | 0.100 |
Why?
| | Electrophysiologic Techniques, Cardiac | 3 | 2018 | 82 | 0.100 |
Why?
| | Computer Simulation | 1 | 2016 | 973 | 0.090 |
Why?
| | Peer Review, Research | 1 | 2012 | 43 | 0.090 |
Why?
| | DNA Methylation | 1 | 2017 | 644 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 4 | 2013 | 2417 | 0.090 |
Why?
| | Bibliometrics | 1 | 2012 | 60 | 0.090 |
Why?
| | Glucocorticoids | 2 | 2013 | 596 | 0.090 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2012 | 80 | 0.090 |
Why?
| | Editorial Policies | 1 | 2012 | 51 | 0.090 |
Why?
| | Intra-Abdominal Fat | 2 | 2024 | 91 | 0.090 |
Why?
| | World Health Organization | 2 | 2022 | 122 | 0.090 |
Why?
| | Myocardial Ischemia | 1 | 2013 | 263 | 0.090 |
Why?
| | Angiogenesis Inhibitors | 1 | 2012 | 226 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1294 | 0.090 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2024 | 326 | 0.090 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2024 | 390 | 0.090 |
Why?
| | Respiration | 2 | 2017 | 197 | 0.080 |
Why?
| | Sclerosis | 1 | 2010 | 13 | 0.080 |
Why?
| | Urinary Bladder | 2 | 2022 | 185 | 0.080 |
Why?
| | Guidelines as Topic | 1 | 2012 | 276 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2045 | 0.080 |
Why?
| | Pituitary-Adrenal System | 1 | 2011 | 162 | 0.080 |
Why?
| | Splenectomy | 1 | 2010 | 62 | 0.080 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2011 | 197 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2017 | 2473 | 0.080 |
Why?
| | Saliva | 1 | 2011 | 241 | 0.080 |
Why?
| | Ultrasonic Therapy | 1 | 2009 | 15 | 0.080 |
Why?
| | Immunoglobulin G | 1 | 2013 | 886 | 0.080 |
Why?
| | Pilot Projects | 3 | 2019 | 1697 | 0.080 |
Why?
| | Exercise | 2 | 2019 | 2038 | 0.080 |
Why?
| | Hydrocortisone | 1 | 2011 | 317 | 0.080 |
Why?
| | Baltimore | 3 | 2015 | 58 | 0.070 |
Why?
| | Lipids | 1 | 2013 | 665 | 0.070 |
Why?
| | Brain | 1 | 2020 | 2669 | 0.070 |
Why?
| | Stroke Volume | 2 | 2022 | 619 | 0.070 |
Why?
| | Heart | 3 | 2017 | 656 | 0.070 |
Why?
| | Organoplatinum Compounds | 2 | 2019 | 46 | 0.070 |
Why?
| | Carcinoma, Islet Cell | 1 | 2008 | 4 | 0.070 |
Why?
| | Internet | 1 | 2012 | 648 | 0.070 |
Why?
| | Referral and Consultation | 1 | 2013 | 777 | 0.070 |
Why?
| | Catheterization, Peripheral | 1 | 2008 | 109 | 0.070 |
Why?
| | Intestinal Neoplasms | 2 | 2004 | 29 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 804 | 0.070 |
Why?
| | Circadian Rhythm | 1 | 2011 | 465 | 0.070 |
Why?
| | Soft Tissue Neoplasms | 1 | 2008 | 114 | 0.070 |
Why?
| | Duodenum | 2 | 2019 | 77 | 0.060 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 5417 | 0.060 |
Why?
| | Radiotherapy | 1 | 2006 | 201 | 0.060 |
Why?
| | Uterus | 1 | 2007 | 215 | 0.060 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2007 | 181 | 0.060 |
Why?
| | Gallbladder Diseases | 1 | 2005 | 12 | 0.060 |
Why?
| | Edetic Acid | 1 | 2005 | 50 | 0.060 |
Why?
| | Sus scrofa | 2 | 2016 | 52 | 0.060 |
Why?
| | Pyridoxal Phosphate | 1 | 2005 | 24 | 0.060 |
Why?
| | Iodized Oil | 3 | 2012 | 4 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2019 | 3537 | 0.060 |
Why?
| | Splenic Vein | 1 | 2004 | 1 | 0.060 |
Why?
| | Portography | 1 | 2004 | 12 | 0.060 |
Why?
| | Portal System | 1 | 2004 | 14 | 0.060 |
Why?
| | Mesenteric Vascular Occlusion | 1 | 2004 | 6 | 0.060 |
Why?
| | Myometrium | 1 | 2005 | 39 | 0.060 |
Why?
| | Receptors, Somatostatin | 1 | 2004 | 25 | 0.060 |
Why?
| | Somatostatin | 1 | 2004 | 61 | 0.060 |
Why?
| | Mesenteric Veins | 1 | 2004 | 22 | 0.050 |
Why?
| | Age Factors | 3 | 2018 | 3290 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 2004 | 88 | 0.050 |
Why?
| | Calibration | 1 | 2024 | 145 | 0.050 |
Why?
| | Body Mass Index | 3 | 2019 | 2364 | 0.050 |
Why?
| | Ovary | 1 | 2025 | 221 | 0.050 |
Why?
| | Peripheral Vascular Diseases | 1 | 2004 | 103 | 0.050 |
Why?
| | Ipilimumab | 1 | 2023 | 33 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2004 | 241 | 0.050 |
Why?
| | Carcinosarcoma | 1 | 2003 | 21 | 0.050 |
Why?
| | Pelvis | 1 | 2024 | 112 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2024 | 117 | 0.050 |
Why?
| | Creatinine | 1 | 2025 | 498 | 0.050 |
Why?
| | Common Bile Duct | 1 | 2022 | 17 | 0.050 |
Why?
| | Intestine, Small | 1 | 2004 | 154 | 0.050 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2006 | 389 | 0.050 |
Why?
| | Heart Aneurysm | 1 | 2002 | 11 | 0.050 |
Why?
| | Registries | 3 | 2018 | 2015 | 0.050 |
Why?
| | X-Rays | 1 | 2022 | 29 | 0.050 |
Why?
| | Kinetics | 2 | 2017 | 1668 | 0.050 |
Why?
| | Financing, Organized | 1 | 2022 | 35 | 0.050 |
Why?
| | Financing, Government | 1 | 2022 | 46 | 0.050 |
Why?
| | Heart Failure | 1 | 2015 | 2228 | 0.050 |
Why?
| | Hormones | 1 | 2022 | 142 | 0.050 |
Why?
| | Aorta, Thoracic | 1 | 2004 | 267 | 0.050 |
Why?
| | Morbidity | 2 | 2013 | 322 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 217 | 0.040 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2021 | 28 | 0.040 |
Why?
| | Anilides | 1 | 2021 | 73 | 0.040 |
Why?
| | Research Support as Topic | 1 | 2022 | 118 | 0.040 |
Why?
| | Fluoroscopy | 1 | 2021 | 157 | 0.040 |
Why?
| | Pedigree | 2 | 2012 | 514 | 0.040 |
Why?
| | Patient Selection | 2 | 2017 | 689 | 0.040 |
Why?
| | Cholinergic Agents | 1 | 2020 | 18 | 0.040 |
Why?
| | Breast | 1 | 2021 | 150 | 0.040 |
Why?
| | Mitomycin | 2 | 2012 | 34 | 0.040 |
Why?
| | Length of Stay | 2 | 2016 | 1208 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2002 | 267 | 0.040 |
Why?
| | Disease Management | 2 | 2014 | 623 | 0.040 |
Why?
| | Preoperative Period | 1 | 2020 | 130 | 0.040 |
Why?
| | Aorta | 1 | 2023 | 417 | 0.040 |
Why?
| | Appendectomy | 1 | 2000 | 79 | 0.040 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2020 | 64 | 0.040 |
Why?
| | Precision Medicine | 1 | 2024 | 426 | 0.040 |
Why?
| | Cachexia | 1 | 2020 | 71 | 0.040 |
Why?
| | Emergencies | 1 | 2000 | 164 | 0.040 |
Why?
| | Hepatitis C | 1 | 2002 | 263 | 0.040 |
Why?
| | Gastroplasty | 1 | 2019 | 30 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2012 | 5749 | 0.040 |
Why?
| | Pancreatic Function Tests | 1 | 2019 | 4 | 0.040 |
Why?
| | Data Accuracy | 1 | 2019 | 63 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2847 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2024 | 890 | 0.040 |
Why?
| | Absorptiometry, Photon | 1 | 2019 | 253 | 0.040 |
Why?
| | Risk | 1 | 2021 | 904 | 0.040 |
Why?
| | Cisplatin | 2 | 2012 | 318 | 0.040 |
Why?
| | Gastric Bypass | 1 | 2019 | 118 | 0.040 |
Why?
| | Paclitaxel | 1 | 2019 | 227 | 0.030 |
Why?
| | Electric Power Supplies | 1 | 2017 | 52 | 0.030 |
Why?
| | Neoplasm Metastasis | 2 | 2012 | 654 | 0.030 |
Why?
| | Global Health | 1 | 2020 | 386 | 0.030 |
Why?
| | Equipment Failure | 1 | 2017 | 108 | 0.030 |
Why?
| | Infant | 3 | 2022 | 9442 | 0.030 |
Why?
| | HCT116 Cells | 1 | 2017 | 80 | 0.030 |
Why?
| | Hemorrhage | 1 | 2022 | 723 | 0.030 |
Why?
| | Child | 4 | 2023 | 21968 | 0.030 |
Why?
| | Camptothecin | 1 | 2017 | 114 | 0.030 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2017 | 63 | 0.030 |
Why?
| | Zinc Finger Protein Gli3 | 1 | 2016 | 3 | 0.030 |
Why?
| | Pain | 1 | 2022 | 755 | 0.030 |
Why?
| | Xenopus Proteins | 1 | 2016 | 37 | 0.030 |
Why?
| | Radionuclide Imaging | 2 | 2008 | 118 | 0.030 |
Why?
| | Databases, Factual | 2 | 2016 | 1347 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2020 | 744 | 0.030 |
Why?
| | Machine Learning | 1 | 2021 | 487 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2022 | 802 | 0.030 |
Why?
| | Exudates and Transudates | 1 | 2015 | 13 | 0.030 |
Why?
| | Equipment Failure Analysis | 1 | 2016 | 132 | 0.030 |
Why?
| | Phenotype | 2 | 2015 | 3199 | 0.030 |
Why?
| | Advisory Committees | 1 | 2017 | 219 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2017 | 3399 | 0.030 |
Why?
| | Echocardiography, Stress | 1 | 2015 | 25 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 584 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 783 | 0.030 |
Why?
| | Models, Animal | 1 | 2016 | 384 | 0.030 |
Why?
| | Heterozygote | 1 | 2015 | 292 | 0.030 |
Why?
| | Sex Factors | 2 | 2015 | 2068 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 318 | 0.030 |
Why?
| | Equipment Design | 1 | 2016 | 522 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2021 | 939 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2017 | 808 | 0.030 |
Why?
| | Geriatric Assessment | 1 | 2015 | 218 | 0.030 |
Why?
| | Compressive Strength | 1 | 2014 | 73 | 0.030 |
Why?
| | Autoradiography | 1 | 2013 | 78 | 0.030 |
Why?
| | Injections, Intra-Arterial | 1 | 2013 | 27 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2013 | 54 | 0.030 |
Why?
| | Anaplasia | 1 | 2013 | 6 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2020 | 1093 | 0.030 |
Why?
| | Netherlands | 1 | 2013 | 88 | 0.030 |
Why?
| | Fractional Flow Reserve, Myocardial | 1 | 2013 | 9 | 0.030 |
Why?
| | Radiology, Interventional | 1 | 2013 | 33 | 0.030 |
Why?
| | Pressure | 1 | 2014 | 222 | 0.030 |
Why?
| | Telomerase | 1 | 2015 | 250 | 0.030 |
Why?
| | Molecular Imaging | 1 | 2013 | 55 | 0.030 |
Why?
| | Cicatrix | 1 | 2013 | 64 | 0.030 |
Why?
| | Pancreatic Juice | 1 | 2012 | 2 | 0.020 |
Why?
| | Chromogranins | 1 | 2012 | 15 | 0.020 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2012 | 43 | 0.020 |
Why?
| | Microcirculation | 1 | 2013 | 145 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 658 | 0.020 |
Why?
| | Heredity | 1 | 2012 | 13 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2013 | 317 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2012 | 164 | 0.020 |
Why?
| | Bilirubin | 1 | 2012 | 97 | 0.020 |
Why?
| | Benzenesulfonates | 1 | 2011 | 22 | 0.020 |
Why?
| | China | 1 | 2012 | 217 | 0.020 |
Why?
| | Hepatitis B, Chronic | 1 | 2011 | 23 | 0.020 |
Why?
| | Asymptomatic Diseases | 1 | 2012 | 87 | 0.020 |
Why?
| | Treatment Failure | 1 | 2012 | 353 | 0.020 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 117 | 0.020 |
Why?
| | Ligands | 1 | 2013 | 664 | 0.020 |
Why?
| | Allostasis | 1 | 2011 | 17 | 0.020 |
Why?
| | Europe | 1 | 2012 | 414 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2012 | 243 | 0.020 |
Why?
| | General Surgery | 1 | 2013 | 169 | 0.020 |
Why?
| | Adrenal Glands | 1 | 2011 | 77 | 0.020 |
Why?
| | Gastroenterology | 1 | 2013 | 181 | 0.020 |
Why?
| | Vasodilator Agents | 1 | 2013 | 331 | 0.020 |
Why?
| | Canada | 1 | 2012 | 420 | 0.020 |
Why?
| | Medical Oncology | 1 | 2013 | 290 | 0.020 |
Why?
| | Action Potentials | 1 | 2013 | 495 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 413 | 0.020 |
Why?
| | Sodium Isotopes | 1 | 2009 | 2 | 0.020 |
Why?
| | Hepatitis C, Chronic | 1 | 2011 | 163 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 432 | 0.020 |
Why?
| | Dexamethasone | 1 | 2011 | 377 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1731 | 0.020 |
Why?
| | Hemodynamics | 1 | 2013 | 1110 | 0.020 |
Why?
| | Thrombosis | 1 | 2012 | 367 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2008 | 329 | 0.020 |
Why?
| | Femoral Artery | 1 | 2007 | 179 | 0.020 |
Why?
| | Blood Glucose | 1 | 2016 | 2180 | 0.020 |
Why?
| | Mass Screening | 1 | 2014 | 1262 | 0.020 |
Why?
| | Child, Preschool | 2 | 2014 | 11069 | 0.020 |
Why?
| | Gallbladder | 1 | 2005 | 19 | 0.010 |
Why?
| | Tissue Survival | 1 | 2005 | 17 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2512 | 0.010 |
Why?
| | Indium Radioisotopes | 1 | 2004 | 14 | 0.010 |
Why?
| | Adenoma, Islet Cell | 1 | 2004 | 8 | 0.010 |
Why?
| | Bone Diseases | 1 | 2005 | 62 | 0.010 |
Why?
| | Radiography, Interventional | 1 | 2005 | 114 | 0.010 |
Why?
| | Mice | 1 | 2020 | 17731 | 0.010 |
Why?
| | Aneurysm, False | 1 | 2002 | 48 | 0.010 |
Why?
| | Research Design | 1 | 2007 | 1107 | 0.010 |
Why?
| | Palliative Care | 1 | 2005 | 743 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2002 | 1045 | 0.010 |
Why?
|
|
Kamel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|